Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation

Blood

Volumn 118, Issue 5, 2011, Pages 1316-1322

  Augereau, Adeline ^a,b   De Roodenbeke, Claire T'kint ^a   Simonet, Thomas ^a   Bauwens, Serge ^a   Horard, Béatrice ^a   Callanan, Mary ^c,d   Leroux, Dominique ^c,d   Jallades, Laurent ^e   Salles, Gilles ^a   Gilson, Eric ^a,b,e,f   Poncet, Delphine ^a,b,c,d,e  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c INSTITUT ALBERT BONNIOT   (France)

^d UNIV GRENOBLE ALPES   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACD GENE; ARTICLE; CANCER PATIENT; CANCER STAGING; CHROMOSOME SIZE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TELOMERE; TINF2 GENE;

EID: 80051553764     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295774     Document Type: Article

References (46)

1. Gilson E, Geli V. How telomeres are replicated. Nat Rev Mol Cell Biol. 2007;8(10):825-838. (Pubitemid 47462137)
2. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8(6):450-458. (Pubitemid 351744962)
3. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell. 1985;43(2 Pt 1):405-413. (Pubitemid 16213265)
4. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015.
5. Brunori M, Luciano P, Gilson E, Geli V. The telomerase cycle: normal and pathological aspects. J Mol Med. 2005;83(4):244-257. (Pubitemid 40674951)
6. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 2000;406(6796):641-645. (Pubitemid 30641052)
7. Rossi D, Lobetti Bodoni C, Genuardi E, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia. 2009;23(6):1062-1072.
8. Poncet D, Belleville A, t'kint de Roodenbeke C, et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood. 2008;111(4):2388-2391. (Pubitemid 351451451)
9. Jahrsdorfer B, Weiner GJ. Short telomeres in B-CLL: the chicken or the egg? Blood. 111(12):5756, 2008; author reply 5756-5757.
10. Ricca I, Rocci A, Drandi D, et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia. 2007;21(4):697-705. (Pubitemid 46444553)
11. Brugat T, Nguyen-Khac F, Grelier A, Merle-Beral H, Delic J. Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood. 2010;116(2):239-249.
12. Lin TT, Letsolo BT, Jones RE, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116(11):1899-1907.
13. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10):1133-1138. (Pubitemid 44527346)
14. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19(18):2100-2110.
15. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301-334.
16. Lei M, Zaug AJ, Podell ER, Cech TR. Switching human telomerase on and off with hPOT1 protein in vitro. J Biol Chem. 2005;280(21):20449-20456. (Pubitemid 40776744)
17. Loayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003;423(6943):1013-1018. (Pubitemid 36806919)
18. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 1997;385(6618):740-743.
19. Wang F, Podell ER, Zaug AJ, et al. The POT1- TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445(7127):506-510. (Pubitemid 46197626)
20. Jiang WQ, Zhong ZH, Henson JD, Reddel RR. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene. 2007;26(32):4635-4647. (Pubitemid 47067407)
21. Nakanishi K, Kawai T, Kumaki F, et al. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res. 2003;9(3):1105-1111. (Pubitemid 36323718)
22. Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev. 2007;21(2):206-220. (Pubitemid 46155814)
23. Biroccio A, Rizzo A, Elli R, et al. TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. Eur J Cancer. 2006;42(12):1881-1888. (Pubitemid 44149082)
24. Blasco MA. The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 2007;8(4):299-309. (Pubitemid 46439289)
25. Garcia-Cao M, O'Sullivan R, Peters AH, Jenuwein T, Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004;36(1):94-99. (Pubitemid 38056214)
26. Benetti R, Gonzalo S, Jaco I, et al. Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination. J Cell Biol. 2007;178(6):925-936. (Pubitemid 47443317)
27. Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol. 2006;8(4):416-424.
28. Mehes G. Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia. Pathol Oncol Res. 2005;11(4):205-210. (Pubitemid 43266922)
29. Matthews C, Catherwood MA, Morris TC, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol. 2006;77(4):309-317. (Pubitemid 44337324)
30. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146(1):64-75.
31. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82(6):1820-1828. (Pubitemid 23278773)
32. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625-1638. (Pubitemid 33126813)
33. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58(21):4918-4922. (Pubitemid 28503691)
34. Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 2005;105(12):4807-4812. (Pubitemid 40807307)
35. Roos G, Krober A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111(4):2246-2252. (Pubitemid 351451432)
36. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13(17):1549-1556. (Pubitemid 37078413)
37. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al.ADNAdamage checkpoint response in telomere- initiated senescence. Nature. 2003;426(6963):194-198. (Pubitemid 37442589)
38. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet. 2007;39(2):243-250. (Pubitemid 46184357)
39. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. (Pubitemid 40322252)
40. Ye JZ, Donigian JR, van Overbeek M, et al. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem. 2004;279(45):47264-47271. (Pubitemid 39518383)
41. O'Connor MS, Safari A, Xin H, Liu D, Songyang Z.A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc Natl Acad Sci U S A. 2006;103(32):11874-11879. (Pubitemid 44215779)
42. Kim SH, Beausejour C, Davalos AR, Kaminker P, Heo SJ, Campisi J. TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem. 2004; 279(42):43799-43804. (Pubitemid 39390685)
43. Tejera AM, Stagno d'Alcontres M, Thanasoula M, et al. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. Dev Cell. 2010;18(5):775-789.
44. Chebel A, Bauwens S, Gerland LM, et al. Telomere uncapping during in vitro T-lymphocyte senescence. Aging Cell. 2009;8(1):52-64.
45. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
46. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet. 2001;28(2):155-159. (Pubitemid 32538061)